SRR975566
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- ANGIOGENESIS+0.380
- G2M_CHECKPOINT+0.370
- MYC_TARGETS_V2+0.310
- MTORC1_SIGNALING+0.250
- ALLOGRAFT_REJECTION+0.230
- HEDGEHOG_SIGNALING+0.210
- WNT_BETA_CATENIN_SIGNALING+0.210
- MYC_TARGETS_V1+0.190
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.400
- XENOBIOTIC_METABOLISM-0.360
- BILE_ACID_METABOLISM-0.310
- ESTROGEN_RESPONSE_LATE-0.300
- P53_PATHWAY-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
- FATTY_ACID_METABOLISM-0.250
- PANCREAS_BETA_CELLS-0.250
- PEROXISOME-0.250
- HEME_METABOLISM-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR975554 | — | — | 0.784 |
| 2 | 7c4477a6-c744-412a-8571-bfb62f0dc714 | — | — | 0.759 |
| 3 | TCGA-68-8251-01A-11R-2296-07 | — | cohortSQ1 | 0.743 |
| 4 | SRR5088924 | — | — | 0.738 |
| 5 | SRR934900 | — | — | 0.727 |
| 6 | TCGA-85-7699-01A-11R-2125-07 | — | cohortSQ1 | 0.726 |
| 7 | TCGA-E2-A1AZ-01A-11R-A12P-07 | — | D | 0.725 |
| 8 | SRR934755 | — | — | 0.723 |
| 9 | TCGA-EW-A1OW-01A-21R-A144-07 | — | E | 0.718 |
| 10 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.717 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.120 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |